Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mine didn't show Russia, bookmarked, thanks
"Kushner Repeatedly Advised Trump the Media Was Exaggerating Coronavirus Threat, Says Report":
https://www.thedailybeast.com/kushner-repeatedly-advised-trump-the-media-was-exaggerating-coronavirus-threat-says-report
How Jared Kushner's family is cashing in on COVID-19 testing:
March 18, 2020
Ah, looks like Bezos is at 119B, and Gates is at 98B.
It is certain that they are lying about the numbers. For the last 2 or three weeks there has been no change.
Not possible
Gates and Bezos will be working together to enslave humanity anyway though.
Mar 11 2020
https://www.cnbc.com/2020/03/11/amazon-care-gates-foundation-may-deliver-coronavirus-tests-in-seattle.html
"Is Amazon Secretly Working on a Cure for the Common Cold?
Maybe...but no one really knows why"
Mar 11, 2020
https://www.popularmechanics.com/science/health/a31293817/amazon-common-cold/
Bill and Bezos go back and forth. I think Bill may be number one right now actually.
However, that's nothing compared to the guy they'd both like to beat.
From 2015...
"Can Bill Gates Become the Richest American in History?":
I noticed afterward that I addressed something that you didn't say, but it was too late to edit. I agree China is likely lying about their numbers.
Not saying it was created by any nation. Just saying that china keeps lying about the numbers.
And they didn't have the balls to notify the world of what was happening, until it was out of control.....
They absolutely HAVE to have a good spin on everything.
Here's a good channel that exposes them for what they are:
https://www.youtube.com/user/NTDChinaUncensored
z
From working out of a garage to being the second most richest man on the planet has perhaps warped his mind.
Or maybe the plan it to kill off the first richest, and everyone else that might challenge his position.
A game to him that he want's to win, maybe
It's even weirder than that. Bill's dad was the head of Planned Parenthood, so he has explained that he grew up with lots of dinner table discussions about population control, abortion, food control, and vaccinations.
Depopulation may be Bill's true passion. Vladimir Putin seems to think so.
We've been here before with the whole China vs. U.S. origin debate. It was the same debate with the Spanish Flu in 1918. The Rockefellers have always loved China, and thought it should be a model for the whole world. The Rockefellers were even training Chinese medical scientists in epidemiology back in 1918:
Can't make this stuff up...EVENT 201:
I'm not the only one noticing. Spread the word:
"Billionaires Try to Shrink World’s Population, Report Says":
May 26, 2009- Wall Street Journal
Been a Rockefeller foundation plan since forever:
"Clip:Rockefeller UN depopulation":
https://www.c-span.org/video/?c4619672/user-clip-rockefeller-depopulation
They are using the virus event to institute a system of digital ID in which identities are on the blockchain. Bill has birth control chips too. This is getting ridiculous. Military people, religious people, and folks who know history should all recognize what's going on with this event. Spread the word.
Always problem, reaction, solution.
The virus was just the problem.
The chip is the solution.
It's all really happening:
"Welcome the City of Austin to the ID2020 Alliance!"
Sep 10, 2019
https://medium.com/id2020/welcome-the-city-of-austin-to-the-id2020-alliance-76b0ebe6776
Partnering for a path to digital identity
Jan 22, 2018
https://blogs.microsoft.com/blog/2018/01/22/partnering-for-a-path-to-digital-identity/
The chip was ready in advance. Published online in October. Fully published in November.
https://pubs.acs.org/doi/10.1021/acsami.9b15032
"Bill Gates will use microchip implants to fight coronavirus":
19-Mar-2020
https://biohackinfo.com/news-bill-gates-id2020-vaccine-implant-covid-19-digital-certificates/
ID2020:
https://id2020.org/
"Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus"
2019 Nov 20
https://www.ncbi.nlm.nih.gov/pubmed/31633330
Good post, lot's of problems in this world for sure. And there could be more added to that list.
“A pandemic has been declared, but not for the 24,600 who die every day from unnecessary starvation, and not for 3,000 children who die every day from preventable malaria, and not for the 10,000 people who die every day because they are denied publicly-funded healthcare, and not for the hundreds of Venezuelans and Iranians who die every day because America's blockade denies them life-saving medicines, and not for the hundreds of mostly children bombed or starved to death every day in Yemen, in a war supplied and kept going, profitably, by America and Britain. Before you panic, consider them,” - Jhon Pilger
I've created a site connecting COVID-19 volunteers to institutions that need them. This is somewhat self-promotion, but it's for a good cause (I’m not profiting from this) and the more people that can help the better, so I thought I'd post it anyway. This site allows people to sign up, and those that need volunteers, like hospitals, can put in their location and we will provide them with a list of people nearby. Anyone in the US can sign up. We have a hospital system in the Seattle area that we are sending volunteers to. They mainly need medical professionals, but they and others have general volunteering needs as well. We expect other hospital systems across the country to follow suit. If you are interested in helping, please volunteer, upvote or share.
Website: https://endcovid.org/volunteers/
I've created a site connecting COVID-19 volunteers to institutions that need them. This is somewhat self-promotion, but it's for a good cause (I’m not profiting from this) and the more people that can help the better, so I thought I'd post it anyway. This site allows people to sign up, and those that need volunteers, like hospitals, can put in their location and we will provide them with a list of people nearby. Anyone in the US can sign up. We have a hospital system in the Seattle area that we are sending volunteers to. They mainly need medical professionals, but they and others have general volunteering needs as well. We expect other hospital systems across the country to follow suit. If you are interested in helping, please volunteer, upvote or share.
Website: https://endcovid.org/volunteers/
I've created a site connecting COVID-19 volunteers to institutions that need them. This is somewhat self-promotion, but it's for a good cause (I’m not profiting from this) and the more people that can help the better, so I thought I'd post it anyway. This site allows people to sign up, and those that need volunteers, like hospitals, can put in their location and we will provide them with a list of people nearby. Anyone in the US can sign up. We have a hospital system in the Seattle area that we are sending volunteers to. They mainly need medical professionals, but they and others have general volunteering needs as well. We expect other hospital systems across the country to follow suit. If you are interested in helping, please volunteer, upvote or share.
Website: https://endcovid.org/volunteers/
Yep, I don't believe them at all
Get some Quercetin...or eat Red Onions.....does the same thing as Chloroquine...both allow Zinc into cells...which slows down the virus:
https://caboftl.com/2020/03/18/coronavirus-tips/
z
INKW HUGE COVID19 FILING out A/H
https://backend.otcmarkets.com/otcapi/company/financial-report/242095/content
$TNXP SOUTHERN RESEARCH, TONIX TEAM TO DEVELOP POTENTIAL VACCINE AGAINST NEW CORONAVIRUS FEBRUARY 26, 2020 | BY JERRY UNDERWOOD | DRUG DEVELOPMENT
https://southernresearch.org/news/southern-research-tonix-team-to-develop-potential-vaccine-against-new-coronavirus/
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.
Tonix is developing TNX-801 – a live horsepox virus vaccine for percutaneous administration — as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a vaccine against monkeypox.
Tonix’s proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents.
Southern Research and Tonix said the new research collaboration will develop and test a potential horsepox vaccine that expresses protein from the virus that causes COVID, a SARS-CoV-2, to protect against the disease.
There are currently no vaccines to protect against COVID-19, which may cause serious complications. The SARS-CoV-2 is reportedly highly infectious and is associated with a significant rate of mortality.
“We look forward to this collaboration to advance a potential COVID-19 vaccine,” said Scott Goebel, a senior scientist in Southern Research’s Drug Development division and principal investigator of the project.
Birmingham-based Southern Research, which has considerable experience in infectious disease research, has long been a leader in the evaluation of vaccine candidates and possible therapeutics for emerging biological threats.
Goebel has previously worked on vaccinia and orthopoxvirus vaccines for other conditions and has studied coronaviruses.
TESTING VACCINE CONSTRUCTS
Under the terms of the research collaboration, Southern Research will test one or more vaccine constructs in the Tonix horsepox vector that express one or more proteins or protein fragments from COVID-19.
The collaboration seeks to leverage Tonix’s horsepox vaccine technology that was originally developed to protect against smallpox but has capabilities as a vector for other infectious diseases.
Tonix has previously reported that horsepox has efficacy as a vaccine and good tolerability in mice and cynomolgus macaques. Horsepox is closely related to vaccinia vaccines, which are a group of orthopoxviruses that have been used as smallpox vaccines. Some vaccinia vaccines have been engineered to express coronavirus proteins and to elicit vaccine responses successfully in the past.
“Although vaccinia vectors are available, different orthopoxvirus strains may behave differently as vectors in part because of their different repertoire of genes that modulate immune responses and host range,” said Dr. Seth Lederman, CEO of Tonix Pharmaceuticals. “Potential advantages of horsepox are the strong immunogenicity we observed in macaques and mice with good tolerability.
“The protein synthesis connected with a replicating live virus vaccine provides direct antigen presentation, which can stimulate cellular immunity in addition to humoral immunity,” added Dr. Lederman, formerly an associate professor at Columbia University who made significant original contributions to immunology.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat pain, addiction and psychiatric conditions.
To see the company’s detailed announcement on the collaboration, click here.
HOME | NEWS | DRUG DEVELOPMENT | SOUTHERN RESEARCH, TONIX TEAM TO DEVELOP POTENTIAL VACCINE AGAINST NEW CORONAVIRUS
VISL (.148) looks good. Their remote monitoring and production solutions could be very beneficial responding to challenges during the pandemic.
https://www.vislink.com/vislink-technologies-issues-response-to-covid-19/
For our customers, we are focused on doing our utmost to help them meet the evolving business and organizational challenges they are facing as a result of this contagion. This includes making sure they are aware of the extensive capabilities our systems offer to assist them in their plans, particularly our ability to craft innovative solutions that allow personnel to be there, even when they aren’t there. In fact, we have several innovative remote production solutions applicable to television broadcasting, but also for the military, government and security sectors, as well as new fields such as remote production facility monitoring which reduces the number of staff required on site.
As the leader in providing video systems that capture, distribute and manage real-time events clearly and reliably, we are well-positioned to help people safely experience, enjoy and keep abreast of business activities and unfolding events as they happen.
Japanese Flu Drug Favipiravir 'Clearly Effective' In Treating Coronavirus, Claims China
Thursday, 19 March 2020
Click For Article
Japanese media said that Zhang Xinmin has claimed that favipiravir, developed by a subsidiary of Fujifilm, had produced good encouraging outcomes in clinical trials conducted on 340 patients in Wuhan and Shenzhen, reported Guardian.
An official at China's Science and Technology Ministry said on Wednesaday that a Japanese flu drug to treat new strains of influenza has proved 'clearly effective' in treating coronavirus patients.
Japanese media said that Zhang Xinmin has claimed that favipiravir, developed by a subsidiary of Fujifilm, had produced good encouraging outcomes in clinical trials conducted on 340 patients in Wuhan and Shenzhen, reported Guardian.
“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters.
Japanese public broadcaster NHK reported that patients who were given the medicine in Shenzhen turned negative for the virus nearly four days after testing postive for the virus.
The X-rays of these patients also showed improvements in lung condition in about 91% of the patients, while it was 62% on those without the drug.
The drug which is also known as Avigan is developed by uFujifilm Toyama Chemical. The pharma company has preferred not to comment on this matter.
Guardian reported that Avigan is being used by Japanese doctors in clinical studies on coronavirus patients with mild to moderate symptoms.
A Japanese health ministry source, however, said that the drug was not as effective in people with more severe symptoms. “We’ve given Avigan to 70 to 80 people, but it doesn’t seem to work that well when the virus has already multiplied,” the source told the Mainichi Shimbun.
Notably, favipiravir was used by the Japanese government in 2016 as an emergency aid to counter the Ebola virus outbreak in Guinea.
It is learnt that Favipiravir would need approval from Japanese government for full-scale use on Covid-19 patients and the drug could be approved as early as May. “But if the results of clinical research are delayed, approval could also be delayed.”
TRUTH
Cuba’s Contribution To Combatting COVID-19
by HELEN YAFFE-MARCH 17, 2020
Click For Article
Photograph Source: NatalieMaynor – CC BY 2.0
COVID-19 surged in the Chinese city of Wuhan in late December 2019 and by January 2020 it had hit Hubei province like a tidal wave, swirling over China and rippling out overseas. The Chinese state rolled into action to combat the spread and care for those infected. Among the 30 medicines the Chinese National Health Commission selected to fight the virus was a Cuban anti-viral drug Interferon Alpha 2b. This drug has been produced in China since 2003, by the enterprise ChangHeber, a Cuban-Chinese joint venture.
Cuban Interferon Alpha 2b has proven effective for viruses with characteristics similar to those of COVID-19. Cuban biotech specialist, Dr Luis Herrera Martinez explained that ‘its use prevents aggravation and complications in patients, reaching that stage that ultimately can result in death.’ Cuba first developed and used interferons to arrest a deadly outbreak of the dengue virus in 1981, and the experience catalysed the development of the island’s now world-leading biotech industry.
The world’s first biotechnology enterprise, Genetech, was founded in San Francisco in 1976, followed by AMGen in Los Angeles in 1980. One year later, the Biological Front, a professional interdisciplinary forum, was set up to develop the industry in Cuba. While most developing countries had little access to the new technologies (recombinant DNA, human gene therapy, biosafety), Cuban biotechnology expanded and took on an increasingly strategic role in both the public health sector and the national economic development plan.
It did so despite the US blockade obstructing access to technologies, equipment, materials, finance and even knowledge exchange. Driven by public health demand, it has been characterised by the fast track from research and innovation to trials and application, as the story of Cuban interferon shows.
Interferons are ‘signalling’ proteins produced and released by cells in response to infections which alert nearby cells to heighten their anti-viral defences. They were first identified in 1957 by Jean Lindenmann and Aleck Isaacs in London. In the 1960s Ion Gresser, a US-researcher in Paris, showed that interferons stimulate lymphocytes that attack tumours in mice. In 1970s, US oncologist Randolph Clark Lee, took up this research.
Catching the tail end of US President Carter’s improved relations with Cuba, Dr Clark Lee visited Cuba, met with Fidel Castro and convinced him that interferon was the wonder drug. Shortly afterwards, a Cuban doctor and a haematologist spent time in Dr Clark Lee’s laboratory, returning with the latest research about interferon and more contacts. In March 1981, six Cubans spent 12 days in Finland with the Finnish doctor Kari Cantell, who in the 1970s had isolated interferon from human cells, and had shared the breakthrough by declining to patent the procedure. The Cubans learned to produce large quantities of interferon.
Within 45 days of returning to the island, they had produced their first Cuban batch of interferon, the quality of which was confirmed by Cantell’s laboratory in Finland. Just in time, it turned out. Weeks later Cuba was struck by an epidemic of dengue, a disease transmitted by mosquitos. It was the first time this particularly virulent strand, which can trigger life-threatening dengue haemorrhagic fever, had appeared in the Americas.
The epidemic affected 340,000 Cubans with 11,000 new cases diagnosed every day at its peak. 180 people died, including 101 children. The Cubans suspected the CIA of releasing the virus. The US State Department denied it, although a recent Cuban investigation claims to provide evidence that the epidemic was introduced from the US.
Cuba’s Ministry of Public Health authorised the use of Cuban interferon to halt the dengue outbreak. It was done at great speed. Mortality declined. In their historical account, Cuban medical scientists Caballero Torres and Lopez Matilla wrote: ‘It was the most extensive prevention and therapy event with interferon carried out in the world. Cuba began to hold regular symposia, which quickly drew international attention’. The first international event in 1983 was prestigious; Cantell gave the keynote speech and Clark attended with Albert Bruce Sabin, the Polish American scientist who developed the oral polio vaccine.
Convinced about the contribution and strategic importance of innovative medical science, the Cuban government set up the Biological Front in 1981 to develop the sector. Cuban scientists went abroad to study, many in western countries. Their research took on more innovative paths, as they experimented with cloning interferon.
By the time Cantell returned to Cuba in 1986, the Cubans had developed the recombinant human Interferon Alfa 2b which has benefited thousands of Cubans since then. With significant state investment, Cuba’s showpiece Centre for Genetic Engineering and Biotechnology (CIGB) was opened in 1986. By then Cuba was submerged in another health crisis, a serious outbreak of Meningitis B, which further spurred Cuba’s biotechnology sector.
Cuba’s Meningitis Miracle
In 1976, Cuba was struck by meningitis B and C outbreaks. Since 1916 only a few isolated cases had been seen on the island. Internationally, vaccines existed for Meningitis A and C, but not for B. Cuban health authorities secured a vaccine from a French pharmaceutical company to immunise the population against type C Meningitis. However, in the following years, cases of type B Meningitis began to rise. A team of specialists from different medical science centres was established, led by a woman biochemist, Concepción Campa, to work intensively on finding a vaccine.
By 1984 Meningitis B had become the main health problem in Cuba. After six years of intense work, Campa’s team produced the world’s first successful Meningitis B vaccine in 1988. A member of Campa’s team, Dr Gustavo Sierra recalled their joy: ‘this was the moment when we could say it works, and it works in the worst conditions, under pressure of an epidemic and among people of the most vulnerable age.’ During 1989 and 1990, three million Cubans, those most at risk, were vaccinated.
Subsequently, 250,000 young people were vaccinated with the VA-MENGOC-BC vaccine, a combined Meningitis B and C vaccination. It recorded 95% efficacy overall, with 97% in the high-risk three months to six years age group. Cuba’s Meningitis B vaccine was awarded a UN Gold Medal for global innovation. This was Cuba’s meningitis miracle.
‘I tell colleagues that one can work 30 years, 14 hours a day just to enjoy that graph for 10 minutes,’ Agustin Lage, Director of the Centro for Molecular Immunology (CIM) told me, referring to an illustration of the rise and sudden fall of Meningitis B cases in Cuba. ‘Biotechnology started for this. But then the possibilities of developing an export industry opened up, and today, Cuban biotechnology exports to 50 countries.’
Since its first application to combat dengue fever, Cuba’s interferon has shown its efficacy and safety in the therapy of viral diseases including Hepatitis B and C, shingles, HIV-AIDS and dengue. Because it interferes with viral multiplication within cells, it has also been used in the treatment of different types of carcinomas. Time will tell if Interferon Alfa 2b proves to be the wonder drug as far as COVID-19 goes.
TRUTH
COVID-19: Could Hydroxychloroquine Really Be the Answer?
By Aude Lecrubier-March 18, 2020
Click For Article
Could the old generic malaria drug hydroxychloroquine (Plaquenil, Sanofi-Aventis, among others), which is also used for the treatment of rheumatic disease, be an essential treatment for COVID-19?
This hypothesis, put forward by some, including Professor Didier Raoult of the IHU Méditerranée Infection in Marseille, was dismissed by other eminent infectious disease specialists and dismissed as fake news recently by the Ministry of Health.
Yet it resurfaced yesterday with the presentation on YouTube by Prof Raoult of positive results in a non-randomised, unblinded trial of 24 patients.
This follows encouraging in vitro results obtained by a Chinese team led by Xueting Yao, from Peking University Third Hospital, Beijing, China, which were published online by the journal Clinical Infectious Diseases on March 9th. However, the data were deemed insufficient by the infection community to recommend the compound as a treatment.
Moreover, chloroquine is not listed among the four treatments studied as part of the recently launched European clinical trial piloted by Inserm, which includes 3200 severe hospitalised patients, including 800 French patients.
Chloroquine was ruled out due to the risk of interactions with other medications for common comorbidities in infected patients, and because of possible adverse effects in patients undergoing resuscitation.
The Marseille Study
The European Union Clinical Trials Register shows that the Marseille study was accepted on 5th March by the National Medicines Safety Agency (ANSM). It could include up to 25 COVID-19 positive patients, comprising five aged 12–17 years, 10 aged 18–64 years, and 10 more aged 65 years or over.
While the data have not yet been published, and should therefore be interpreted with caution, this non-randomised, unblinded study showed a strong reduction in viral load with hydroxychloroquine.
After 6 days, the percentage of patients testing positive for COVID-19 who received hydroxychloroquine fell to 25% versus 90% for those who did not receive the treatment (a group of untreated COVID-19 patients from Nice and Avignon).
In addition, comparing untreated patients, those receiving hydroxychloroquine and those given hydroxychloroquine plus the antibiotic azithromycin, the results showed there was "a spectacular reduction in the number of positive cases" with the combination therapy, said Prof Raoult.
At 6 days, among patients given combination therapy, the percentage of cases still carrying SRAS-CoV-2 was no more than 5%.
Azithromycin was added because it is known to be effective against complications from bacterial lung disease but also because it has been shown to be effective in the laboratory against a large number of viruses, the infectious disease specialist explained.
"Everyone who died from COVID-19 were still carriers of coronavirus. To no longer have the virus changes the prognosis," Prof Raoult said.
More detailed results of the study have been submitted for publication in the International Journal of Antimicrobial Agents.
Study Splits Infectious Disease Community
The announcement of positive results from this small study split medical opinion.
Professor Gilles Pialoux, an infectious disease specialist at Tenon Hospital, was cautious in his response. He told Medscape's French Edition: "The idea is interesting but we need large, randomised, controlled trials. We should not communicate this kind of information on YouTube, it is not meaningful.
"Don’t forget, this compound has not been included in Inserm’s trial because there are more interesting avenues, such as remdesivir or Kaletra [lopinavir/ritonavir]. We must be careful not to repeat the story with cyclosporin in HIV."
Christian Perronne, head of infectious diseases, University Hospital Raymond Poincaré, Garches, Paris, was more enthusiastic.
"I really believe in hydroxychloroquine. It is a drug I find rather fascinating, that has been used for decades. There have been positive results in an in vitro study and a preliminary Chinese study in 100 patients which showed that hydroxychloroquine reduced the viral load, the symptoms lasted for less time, and they are not as severe. This could reduce the number of carriers, which I find interesting from an epidemiological perspective.
"I think from an ethical point of view, we should suggest it to all patients with severe disease who are hospitalised, under surveillance and on short treatment, paying attention to drug interactions, especially with drugs that prolong the QT interval. Afterwards, in terms of adverse effects, at increased doses, it is possible that patients will have pain or fever, but it seems that the treatment is effective at lower doses, according to the Chinese data. In any case, the adverse effects of this compound are not dangerous."
On the adverse effects, Professor Thomas Papo, from Bichat Hospital, the University of Paris, confirmed via email: "Hydroxychloroquine (Plaquenil, which is not chloroquine), vaunted by Didier Raoult as an anti-viral, has been used for decades in tens of thousands of patients, for several decades, so we have a huge follow-up and lots of data. This drug is remarkably well tolerated and we give it to all patients with lupus (for example), including in pregnant women. The main complication (retinal toxicity) is rare and does not last beyond 5 years of continuous use."
Hydroxychloroquine Tested in Other Hospitals
At the end of Tuesday’s Council of Ministers, Sibeth Ndiaye, a government spokesperson, discussed the results published by Prof Raoult. "The clinical trial in Marseille is a promising start; we are extending it because science requires the experience to be validated and repeated several times to be able to say whether or not it works," she warned. Other tests will be carried out at Lille Hospital to confirm, or not, Prof Raoult’s results.
Chloroquine is currently being examined in a number of clinical studies in China and elsewhere, and some in France have also decided to suggest it following Prof Raoult’s findings.
This is the case for Dr Alexandre Bleibtreu, an internal medicine specialist at Pitié Salpêtrière Hospital, Paris, who was initially not persuaded by the in vitro data but has changed his opinion after having seen the results of the study carried out by Didier Raoult.
Contacted by CheckNews, the on-demand journalism service from Liberation, he explained that the compound was now used in almost all (approximately 50) hospitalised patients in their service, except those who refuse it or who have contraindications.
"I heard about the results, which changed my mind. We followed the Marseille protocol, and there are surely others who will use it. It is not the most obvious treatment; it works in vitro but we didn’t have data in vivo.
"The aim is not to be right but that our patients get better. No treatment is magic and the publication of the results raises questions but between doing nothing and repositioning drugs based on their adverse effects, interactions, etc, we try things as we go."
Scientific Rationale
In the UK, Robin May, Professor of Infectious Disease at the University of Birmingham, explained that there is a scientific rationale for the use of hydroxychloroquine in the treatment of COVID-19, based on its mode of action in malaria.
In a statement through the Science Media Centre, he explained that, as chloroquine is a "weak base" and so helps to neutralise acids, it makes the environment "less suitable" for the malaria parasite to live in when it diffuses into red blood cells.
While the mode of action against COVID-19 is not established, Prof May said, he pointed out that many viruses enter host cells via endocytosis, as a result of which they are initially taken up into an intracellular 'compartment that is "typically fairly acidic”.
"Chloroquine would alter the acidity of this compartment, which can interfere with the ability of viruses to escape into the host cell and start replicating.”
He continued: "Another possibility is that chloroquine may alter the ability of the virus to bind to the outside of a host cell in the first place,” adding that the drug "has subtle effects on a wide variety of immune cells…and it may be that one of these effects helps stimulate the body’s ability to fight off COVID-19.”
Crucially, the drug is also "cheap and relatively easy to manufacture" and so could easily be put into clinical trials and, eventually, treatment, May underlined.
The study by Yao et al was supported by the "13th Five-Year" National Major New Drug Projects of China, Ministry of Science and Technology of the People’s Republic of China, and Bill & Melinda Gates Foundation.
Two of its authors have patents pending for an anti-microbial infection pharmaceutical composition and its application.
Professor Pialoux has been a board member or attended meetings for Gilead, MSD, Bristol-Myers Squibb, Janssen, Abbvie, AstraZeneca.
Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237
Translated and adapted from Medscape's French edition.
Editor's note, 18th March 2020: This article was updated to include Prof May's comments.
TRUTH
APDN 7.45 was over $10 after hours last night.
Applied DNA Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection
https://finance.yahoo.com/news/applied-dna-leverages-covid-19-110000760.html
$CAPR Announced that it has filed provisional patent applications with the United States Patent and Trademark Office for an exosome-based vaccine platform technology, and specifically for potentially combatting the coronavirus disease 2019 (COVID-19) caused by the SARS coronavirus 2 (SARS-CoV-2).
$CAPR Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Wed March 18, 2020 4:01 PM|GlobeNewswire|About: CAPR
-To Report Final 12-month HOPE-2 Data in the Second Quarter-
-Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus-
-To Host Conference Call and Webcast Today at 4:30 p.m. ET-
LOS ANGELES, March 18, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced its financial results for the fourth quarter and full year 2019 and provided a corporate update.
“We continue to make progress toward the goal of bringing CAP-1002 to patients with DMD with our final 12-month data expected in the second quarter. Importantly, we continue to expand our exosomes technology where we are aiming to develop a platform of exosomal-based vaccines that could potentially be beneficial in many indications, including infectious diseases such as the novel coronavirus (SARS-CoV-2). Further, we have strengthened our program with the appointment of Dr. Stephen Gould from Johns Hopkins University as an Executive Consultant to oversee our exosomes program. With our recent financing completed at the end of last year, we now have extended our runway through the second quarter of 2021 to deliver on our milestones and we continue to pursue potential strategic partnerships for our technologies. Over the next few months, we look forward to making more announcements focusing on our late-stage clinical program and our expanding exosomes program,” said Linda Marbán, Ph.D., Capricor’s president and chief executive officer.
Dr. Marbán further noted, “The fourth quarter and 2019 have been encouraging on multiple levels and we will be providing an overview on pipeline and regulatory developments, Key Opinion Leader support and increased financial discipline.”
The 24th International Congress of the World Muscle Society provided an exciting venue for the Company’s “late breaking” presentation unveiling our 6-month interim results in the Phase II HOPE-2 clinical trial of CAP-1002. This was a significant milestone not only for 2019 but also for the clinical pathway of CAP-1002 for DMD.
Ongoing and active communications with the FDA have been productive for Capricor, as we have the unique advantage for more frequent collaborations with the agency due to our RMAT Designation. The FDA has granted Capricor Orphan Drug Designation and a Rare Pediatric Disease Designation to CAP-1002 for the treatment of DMD. If Capricor were to receive market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher.
Capricor expects 2020 to be a transformative year with clarity on next steps in its DMD program and the planned expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases, among other things.
“Building on the success and clinical evidence of our core cardiosphere-derived cells technology, we are enthusiastic to expand our knowledge of exosomes by building out a platform and utilizing our experience to engineer exosomes as drug delivery vehicles,” Dr. Marbán said.
Fourth Quarter & FY Highlights and Recent Operational Developments
Pipeline Development
Announced strategic plan for exosomes platform technology expansion (March 2020)
Announced appointment of Stephen Gould, Ph.D. of Johns Hopkins University as Executive Consultant to oversee exosomes program (March 2020)
Capricor’s exosomes technology highlighted in Nature Biomedical Engineering (January 2020)
Reported positive data from ongoing HOPE-2 Study of CAP-1002 in DMD at World Muscle Society: Data demonstrated improved PUL 2.0 performance at 6 Months. (October 2019)
Reported that our independent Data and Safety Monitoring Board (DSMB) completed their safety assessment and futility analysis review of the HOPE-2 study and recommended that the trial continue. (July 2019)
Reported interim analysis performed on 6-month data from the HOPE-2 trial showed meaningful results across several independent clinical measures. (July 2019)
Hosted a webinar with Parent Project Muscular Dystrophy to discuss updates on the HOPE-2 clinical program. (July 2019)
HOPE-Duchenne (Phase I/II) clinical data was published in the Journal of Neurology (February 2019)
Regulatory Advancement
Plan to meet with the FDA after receipt of the final 12-month data from HOPE-2 to discuss next steps for the program
Met with FDA under a Type B End-of-Phase 2 meeting to discuss pre-specified interim analysis for the HOPE-2 trial. (October 2019)
Key Opinion Leader Support
Updated results from the interim analysis presented at the 24th International Annual Congress of the World Muscle Society
A study of CAP-1002 in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy, HOPE-2. (October 2019)
Hosted a presentation on Dystrophin Deficient Muscular Dystrophy: Diagnosis, Natural History and Current Therapies presented by Dr. Craig McDonald from UC Davis. (October 2019)
Strategic Alignment and Financial Discipline
Completed approximate $5.1 Million offering priced at-the-market. (December 2019)
As of December 31, 2019 – Capricor had approximately $9.9 million of cash, cash equivalents and marketable securities and utilizing conservative cash deployment has extended the company’s runway through at least the second quarter of 2021.
Anticipated Events and Targeted Milestones for 2020
Plan to host a KOL call on exosomal-based vaccines featuring Dr. Stephen Gould
Plan to host a KOL call on cardiac complications of DMD on April 1, 2020 featuring Michael Taylor, M.D., Ph.D. (Cincinnati Children's Hospital)
Plan to submit IND for DMD using CDC-exosomes
Plan to announce final 12-month data for HOPE-2 in Q2-2020
Plan to meet with the FDA to discuss next steps for the DMD program after receipt of the final 12-month data
Plan to present HOPE-2 final results at medical conference
Continue to pursue partnership opportunities for DMD program
Continue to pursue grant funding opportunities for our product candidates
Continue to advance exosome platform opportunities including additional product and indications expansion
Fourth Quarter and Full Year Financial Results
The Company reported a net loss of approximately $1.5 million, or $0.34 per share, for the fourth quarter of 2019, compared to a net loss of approximately $3.3 million, or $1.05 per share, for the fourth quarter of 2018.
As of December 31, 2019, the Company’s cash, cash equivalents and marketable securities totaled approximately $9.9 million, compared to approximately $7.3 million on December 31, 2018. Additionally, in 2019, Capricor raised approximately $4.8 million in net proceeds at an average price of approximately $4.48 per share under its at-the-market offering programs.
Capricor believes that based on the current operating plan and financial resources, the Company expects that the cash, cash equivalents and marketable securities at December 31 will be sufficient to cover expenses and capital requirements through at least the second quarter of 2021.
Conference Call and Webcast
To participate in the conference call, please dial 877-451-6152 (Domestic/Toll-Free) or 201-389-0879 (International) and reference the conference ID: 13699780
To participate via a webcast, please visit: http://public.viavid.com/index.php?id=138327
The webcast will be archived for approximately 30 days and will be available at http://capricor.com/news/events/.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the age of 30, most commonly from heart failure. It occurs in one in every 3,600 live male births across all races, cultures and countries. Duchenne muscular dystrophy afflicts approximately 200,000 boys and young men around the world. Treatment options are limited, and there is no cure.
About CAP-1002
CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity, and is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 150 human subjects across several clinical trials.
About Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the companies investigating the field of extracellular vesicles and is exploring the potential of exosome-based candidates to treat a variety of disorders. For more information, visit www.capricor.com.
Keep up with Capricor on social media: www.facebook.com/capricortherapeutics, www.instagram.com/capricortherapeutics/ and https://twitter.com/capricor
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 29, 2019, and as amended by its Amendment No. 1 to Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on April 1, 2019, in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 8, 2019, and in its Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on December 5, 2019 and the prospectus contained therein, together with any amendments and supplements thereto. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Investor Contact:
Joyce Allaire - Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
(617) 435-6602
Company Contact:
AJ Bergmann, Chief Financial Officer
+1-310-358-3200
abergmann@capricor.com
UPDATED AGAIN "Globally, about 3.4% of reported #COVID19 cases have died. By comparison, seasonal flu generally kills far fewer than 1% of those infected"-@DrTedros #coronavirus #COVID19 ASYMPTOMATIC TRANSMISSION. Case study of #coronavirus transmission from a #asymptomatic person to 5 family members @JAMA_current. #publichealth #globalhealthhttps://t.co/5PMs1ZMr8w In Daegu, 1900 Shincheonji Church members have been tested for coronavirus. I think most people aren’t aware of the risk of systemic healthcare failure due to #COVID19 because they simply haven’t run the numbers yet. Let’s talk math. 1/n
SARS-CoV-2 is the name of the novel Coronavirus we are talking about.
COVID-19 is the respiratory disease caused by the virus.
———————————
Properties of SARS-CoV-2:
80% SARS.
HIV-like mutations.
Incredibly infectious.
Long incubation period.
Aerosol transmission in some cases.
Transmission from asymptomatic people.
It can invade the central nervous system and shut down AUTOMATIC BREATHING.
10-20% end up in the ICU.
The disease acts like a combination of SARS, MERS and AIDS
Also, It either reinfects, never leaves and/or is biphasic.
———————————
It’s clearly highly contagious as seen by the spread. There are many estimates of R0’s. They range from 1.5 to as high as 7. (R0 is the measure of how infectious a virus is)
However, it’s an ever changing figure and can be drastically different in different situations. Regular flu is 1.5
Flu has a mortality rate of 1/10th of one percent = .1%
WHO has stated that the mortality rate for COVID-19 is 3.4%
80% SARS and HIV-like mutations https://www.scmp.com/news/china/society/article/3052495/coronavirus-far-more-likely-sars-bond-human-cells-scientists-say
"Pre-symptomatic transmission may be essential to consider for containment and mitigation strategies for COVID-19"
https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html
Early tweets about Asymptomatic transmission
1300 had symptoms & 600 did not.
Among those 1300 with symptoms, 87.5% were confirmed with the virus .
BUT out of the 600 WITHOUT symptoms, 70% were confirmed with coronavirus.
https://www.reuters.com/article/us-china-health-study-idUSKBN20G00J
This is just one of many reports of people being reinfected. We still don’t know if it’s biphasic, never leaves the body or if it’s actually reinfection. But, the long incubation period may play into that as well.
https://twitter.com/edodriscoll/status/1232972043517341697?s=21
Second infection is worse
https://nypost.com/2020/02/19/whistleblower-doctors-say-coronavirus-reinfection-even-deadlier/
Incubation period
https://www.pharmaceutical-technology.com/news/coronavirus-incubation-period-27-days/
Aerosol/Airborne transmission
https://twitter.com/kr3at/status/1237906079197155331?s=21
Aerosol transmission
“The tests show that when the virus is carried by the droplets released when someone coughs or sneezes, it remains viable, or able to still infect people, in aerosols for at least three hours.”
https://www.reuters.com/article/us-health-coronavirus-study-idUSKBN2143QP
Paper discussing it invading the central nervous system and shutting down AUTOMATIC BREATHING https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25728
“The influence of COVID-19 on the human body is like a combination of SARS and AIDS as it damages both the lungs and immune systems,”
https://www.news.com.au/lifestyle/health/health-problems/chinese-doctors-say-coronavirus-like-a-combination-of-sars-and-aids-can-cause-irreversible-lung-damage/news-story/f58f19c5eeae99b845c54e2d2b9305ca
Beijing announcement on March 5th proving central nervous system infection
https://flutrackers.com/forum/forum/-2019-ncov-new-coronavirus/china-2019-ncov/831003-china-covid-19-cases-outbreak-news-and-information-week-9-10-february-23-march-8-2020/page5
This article talks about the fact that some viruses don’t leave the body. This particular virus is very good at hiding https://www.express.co.uk/news/science/1253132/Coronavirus-news-infection-COVID19-for-life-virus-warning-latest-coronavirus
“Neurological symptoms fall into three categories: central nervous system (CNS) symptoms or diseases (headache, dizziness, impaired consciousness, ataxia, acute cerebrovascular disease, and epilepsy), peripheral nervous system (PNS) symptoms (hypogeusia, hyposmia, hypopsia, and neuralgia), and skeletal muscular symptoms”
https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v1
Kills lung cells and makes the immune system go haywire, “If a severe infection takes hold it may move on to cause damage or dysfunction to the stomach, intestines, heart, liver and kidneys, and even provoke organ failure”
https://www.dailymail.co.uk/health/article-8065483/How-does-coronavirus-attack-human-body.html
10% of confirmed cases go to the ICU. That’s will overwhelm any city and all hospitals
https://twitter.com/marcelsalathe/status/1235662457261023232?s=
Amazing twitter thread about the health care system being overloaded
Covid-19 USA tracker site
https://covidtracking.com/data/
DYNT (1.04) could move back to $2 range. They make Protex Spray and Wipes, which are effective against viruses.
https://www.dynatronics.com/protex_coronavirus_statement
$AYTU News Out - Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy
#Coronavirus #CV #ChineseVirus #COVID2019 #CoronavirusOutbreak #coronavirustesting
https://finance.yahoo.com/news/aytu-bioscience-announces-acceleration-u-155500305.html
DECN'S GenViro!(TM) Corona Virus "Swift" Kit, Now to Be Additionally Offered to Commercial Labs and Religious Groups as 12 Month Forecast is Raised to 525MM
https://finance.yahoo.com/news/decns-genviro-tm-corona-virus-141500357.html
$SOLI CareClix Now Offering COVID-19 Testing Kits
Solei Systems, Inc. (OTC PINK:SOLI) announces that its subsidiary, CareClix, Inc., an industry leader in telemedicine, is now providing screening and testing for Coronavirus disease 2019 (COVID-19) to patients in the comfort and safety of their own home.
https://www.accesswire.com/580865/CareClix-Now-Offering-COVID-19-Testing-Kits
I created a CoronaVirus info/tips page:
https://caboftl.com/2020/03/14/coronavirus-tips/
Please pass it on..........save some lives......
z
I think you should. But of course I am not a health expert. Obviously consult your doctor. But yes, look into it.
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
484
|
Created
|
01/21/20
|
Type
|
Premium
|
Moderator makinezmoney | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |